Partners 2007 Gp, L.P.Presi... Net Worth

The estimated Net Worth of Partners 2007 Gp, L.P.Presi... is at least $3.89 Million dollars as of 24 July 2018. Partners Presi owns over 500,000 units of Menlo Therapeutics stock worth over $66,029 and over the last 7 years Partners sold MNLO stock worth over $3,825,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Partners Presi MNLO stock SEC Form 4 insiders trading

Partners has made over 1 trades of the Menlo Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently Partners sold 500,000 units of MNLO stock worth $3,825,000 on 24 July 2018.

The largest trade Partners's ever made was selling 500,000 units of Menlo Therapeutics stock on 24 July 2018 worth over $3,825,000. On average, Partners trades about 166,667 units every 0 days since 2018. As of 24 July 2018 Partners still owns at least 48,910 units of Menlo Therapeutics stock.

You can see the complete history of Partners Presi stock trades at the bottom of the page.

Insiders trading at Menlo Therapeutics

Over the last 7 years, insiders at Menlo Therapeutics have traded over $3,825,000 worth of Menlo Therapeutics stock and bought 3,655,938 units worth $21,205,011 . The most active insiders traders include Advisors Llcperceptive Life..., Llc Fmr, and Albert Cha. On average, Menlo Therapeutics executives and independent directors trade stock every 85 days with the average trade being worth of $572,944. The most recent stock trade was executed by Sharon Barbari on 20 August 2020, trading 75,000 units of MNLO stock currently worth $111,000.

What does Menlo Therapeutics do?

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.

Complete history of Partners Presi stock trades at Menlo Therapeutics

Menlo Therapeutics executives and stock owners

Menlo Therapeutics executives and other stock owners filed with the SEC include:

• Elisabeth Sandoval,
  Independent Director
• Patrick LePore,
  Independent Director
• Anthony Bruno,
  Director
• Rex Bright,
  Director
• Sharon Barbari,
  Director
• Matthew Wiley,
  Chief Commercial Officer
• Mutya Harsch,
  Chief Legal Officer, General Counsel
• Ronald Krasnow,
  Chief Compliance Officer
• Iain Stuart,
  Chief Scientific Officer
• Andrew Saik,
  Chief Financial Officer, Treasurer
• David Domzalski,
  Chief Executive Officer, Director
• Steven L Basta,
  Director
• Advisors Llcperceptive Life...,
  
• Ilan Hadar,
  CFO and Country Manager
• Stanley Hirsch,
  Director
• Partners 2007 Gp, L.P.Presi...,
  
• Global Strategic Fund Ii L....,
  10% owner
• Ventures Llc Remeditex,
  10% owner
• Capital Viii, Llc Vivo Capi...,
  
• Albert Cha,
  Director
• Llc Fmr,
  
• Scott M Whitcup,
  Director
• Mary Spellman,
  Chief Medical Officer
• Kristine M Ball,
  See Remarks
• David W J Mcgirr,
  Director
• Paul L Berns,
  Director
• Ted Ebel,
  Director
• Aaron Royston,
  Director
• Paul Kwon,
  Chief Scientific Officer